Filtered By:
Condition: Heart Disease
Therapy: Corticosteroid Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 19 results found since Jan 2013.

Prevention of Stroke in Rheumatoid Arthritis
Abstract The risk of cerebrovascular disease is increased among rheumatoid arthritis (RA) patients and remains an underserved area of medical need. Only a minor proportion of RA patients achieve suitable stroke prevention. Classical cardiovascular risk factors appear to be under-diagnosed and undertreated among patients with RA. Reducing the inflammatory burden is also necessary to lower the cardiovascular risk. An adequate control of disease activity and cerebrovascular risk assessment using national guidelines should be recommended for all patients with RA. For patients with a documented history of cerebrovascu...
Source: Current Neurology and Neuroscience Reports - October 20, 2015 Category: Neuroscience Source Type: research

Effect of Bronchodilator and Steroid Use on Heart Disease and Stroke Risks in a Bronchiectasis –Chronic Obstructive Pulmonary Disease Overlap Cohort: A Propensity Score Matching Study
Conclusions: Compared with patients without bronchiectasis and COPD, BCOS patients with recent SABAs, past ICSs, and past anti-arrhythmia drugs use; a low or medium SABAs ICSs, and OSs dose; and a low SAMAs dose had a higher risk of HDS. LAMAs were not associated with HDS.
Source: Frontiers in Pharmacology - November 26, 2019 Category: Drugs & Pharmacology Source Type: research

Management of postoperative atrial fibrillation after cardiac surgery
This article will review the available evidence on the prevention and treatment of atrial fibrillation after cardiac surgery. Using this knowledge, we propose a conceptual framework on the management of patients with POAF during various phases after cardiac surgery. Recent findings: Perioperative β-blockade is the cornerstone in preventing POAF after cardiac surgery. Results from randomized trials do not support routine use of colchicine or corticosteroids to prevent POAF. There is no study examining the impact of rate versus rhythm control on ‘hard’ clinical outcomes such as mortality or stroke in the cardiac surgic...
Source: Current Opinion in Cardiology - February 5, 2016 Category: Cardiology Tags: VALVULAR HEART DISEASE: Edited by Subodh Verma Source Type: research

Controversial cardiovascular and hematologic comorbidities in atopic dermatitis
AbstractAtopic dermatitis ’ (AD) systemic involvement is wide-reaching. The cardiovascular and hematological comorbidities of AD have potential for considerable economic and physical burden; however, data surrounding the association between these comorbidities and AD is controversial. This review discusses the cardiovascul ar and hematological comorbidities of AD, detailing the conflicting evidence, pathophysiology, and connection to medications. A PubMed search was conducted for studies detailing the association of cardiovascular and hematological comorbidities with AD, providing approximately 30 results. Additional sea...
Source: Archives of Dermatological Research - May 10, 2021 Category: Dermatology Source Type: research

What to Know About High Triglycerides
Discussions about heart health often center around blood pressure and cholesterol, with factors like poor sleep, smoking, family history of heart disease, and chronic stress thrown in. However, there’s one variable that doesn’t get covered as often, even though it can be an important indicator of cardiovascular risk: triglycerides. “We don’t really talk about triglycerides very much, especially compared to cholesterol, but they’re actually an essential part of understanding heart health,” says Dr. Adriana Quinones-Camacho, a cardiologist at NYU Langone Health in New York. “For some...
Source: TIME: Health - May 23, 2023 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized healthscienceclimate heart health Source Type: news

Gout: Sleep apnea may raise your risk
Gout is the most common type of inflammatory arthritis and affects more than 8 million adults. Men are at a higher risk than women. And according to a new study, your risk for gout also climbs if you suffer from sleep apnea, a condition where your breathing repeatedly pauses while you sleep. What exactly is gout? Gout is triggered by the crystallization of uric acid within the joints. It happens like this: Your body produces uric acid from breaking down purines, a natural waste product of living cells. Normally, uric acid is dissolved in your blood and passes through your kidneys into your urine. However, sometimes your bo...
Source: New Harvard Health Information - November 17, 2015 Category: Consumer Health News Authors: Matthew Solan Tags: Arthritis Health Sleep gout sleep apnea Source Type: news

Lupus Damage and Waist Circumference as the Independent Risk Factors for Cardiovascular Disease in SLE Patients from Phramongkutklao Hospital.
CONCLUSION: Lupus damage, waist circumference more than 90 centimeters in male or more than 80 centimeters in female were the independent risk factors for CVD in SLE patients. PMID: 27276740 [PubMed - in process]
Source: Journal of the Medical Association of Thailand = Chotmaihet thangphaet - June 11, 2016 Category: Journals (General) Tags: J Med Assoc Thai Source Type: research

The international St-aging system as a prognostic marker in general senior population: Findings from the EPIDOS cohort study.
In conclusion, community-dwelling older women with abnormal ISS had shorter survival time than the others, suggesting that ISS could be considered as a universal prognostic "aging system" rather than a specific MM "staging system". PMID: 31387843 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - August 2, 2019 Category: Internal Medicine Authors: Pouzoullic M, Schott AM, Sánchez-Rodríguez D, Bataille R, Annweiler C, SOCOS group Tags: Eur J Intern Med Source Type: research

Prevalence of the age-related diseases in older patients with acquired thrombotic thrombocytopenic purpura.
CONCLUSIONS: Our findings suggest that a careful comprehensive geriatric assessment of acquired TTP patients is necessary. It is important to look for other autoimmune diseases and such age-related comorbidities as osteoporosis, arterial hypertension, ischemic heart disease and cerebrovascular disease. PMID: 32201091 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - March 18, 2020 Category: Internal Medicine Authors: Agosti P, Mancini I, Gianniello F, Bucciarelli P, Artoni A, Ferrari B, Pontiggia S, Trisolini SM, Facchini L, Carbone C, Peyvandi F, Italian Group of TTP Investigators Tags: Eur J Intern Med Source Type: research

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news